STOCK TITAN

InflaRx N.V. - IFRX STOCK NEWS

Welcome to our dedicated news page for InflaRx N.V. (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on InflaRx N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InflaRx N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InflaRx N.V.'s position in the market.

Rhea-AI Summary
InflaRx N.V. appoints Jan Medina as Vice President and Head of Investor Relations, bringing extensive experience in the life sciences sector and capital markets. The move aims to enhance investor relations and strengthen relationships with the investor community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management
-
Rhea-AI Summary
InflaRx Pharmaceuticals Inc. has launched The InflaRx Commitment Program to cover the costs of GOHIBIC (vilobelimab) for patients who do not survive after being treated in line with its Emergency Use Authorization (EUA) for COVID-19. The program aims to encourage medical facilities to stock GOHIBIC and provide access to this potentially life-saving therapy. The FDA-authorized drug has shown improved survival rates in a multicenter Phase III trial, with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
Rhea-AI Summary
InflaRx N.V. (Nasdaq: IFRX) announces positive topline results from the MAD part of the Phase I trial for INF904, an orally administered low molecular weight C5aR inhibitor. INF904 demonstrated favorable pharmacokinetic and pharmacodynamic data, well tolerated with no safety concerns, and achieved ≥90% blockade of C5a-induced neutrophil activation over the 14-day dosing period. InflaRx plans to advance INF904 into Phase II clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.37%
Tags
clinical trial
Rhea-AI Summary
InflaRx N.V. has initiated a Phase III study to investigate the efficacy and safety of vilobelimab in treating ulcerative pyoderma gangrenosum (PG), a rare and debilitating autoimmune skin disease. The study aims to enroll patients worldwide and has received Fast Track and Orphan Drug designations from regulatory authorities in the U.S. and Europe. The primary endpoint of the study is complete closure of the target ulcer within 26 weeks of treatment initiation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
clinical trial
-
Rhea-AI Summary
InflaRx announces positive Phase I results for INF904, initiates Phase III trial for vilobelimab, and submits MAA for septic ARDS treatment. Commercial sales of Gohibic recorded. Cash and marketable securities of €113 million expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
earnings
-
Rhea-AI Summary
InflaRx announces positive results from Phase I trial of INF904, demonstrating excellent safety and tolerability profile, favorable PK and PD profiles, and potential for long-term treatment of chronic inflammatory conditions. INF904 achieved ≥90% blocking of C5a-induced neutrophil activation at disease relevant C5a levels. Company to present results from ongoing multiple ascending dose (MAD) part of the study in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
clinical trial
Rhea-AI Summary
InflaRx submits MAA for vilobelimab, EMA validates and reviews it. Submission based on PANAMO Phase III trial data showing 23.9% reduction in mortality. EUA received in the US. Company to attend upcoming scientific and investor events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
covid-19
-
Rhea-AI Summary
InflaRx N.V. announced financial results for Q2 2023 and provided an operating update. The company highlighted the EUA and commercial launch of Gohibic (vilobelimab) in the US, progress in clinical development of vilobelimab in other indications, addition of Camilla Chong as Chief Medical Officer, and a cash position of €115.2 million. They also provided updates on the development of vilobelimab in pyoderma gangrenosum and cutaneous squamous cell carcinoma, as well as the progress of their oral C5aR inhibitor INF904.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.59%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
management
Rhea-AI Summary
InflaRx announces the commercial launch of Gohibic (vilobelimab) in the U.S. for the treatment of critically ill COVID-19 patients under an Emergency Use Authorization (EUA) granted by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
InflaRx N.V.

Nasdaq:IFRX

IFRX Rankings

IFRX Stock Data

103.05M
46.05M
12.04%
29.18%
0.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Jena

About IFRX

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe